Avid Bioservices Inc (CDMO)

[jazzbeerman]

correct steve,

Bavi's competition in the HCV space is the common/fundamental ingredient of HCV SOC therapy- interferon, and if bavi remains successful/safe it would be paired with ribavirin, and hopefully the newer antivirals if they remain successful/safe.
(and that's been the plan all along).

Steve King even, for the first time, recently compared Bavi's HCV efficacy to interferon, at the Bio Investors Conf. presentation.

Did any of you catch the comment??.....

SK: "For the HCV program we've completed two clinical studies in HCV infected patients, a single dose monotherapy study, and a repeat dose monotherapy study. In both cases the drug appeared safe and well-tolerated. In addition we did see some encouraging signs of antiviral activity, highlighted in the repeat-dose study by the fact that half of the patients at the 3mg/kg dose level had about an average of a one log or a 90% peak reduction in viral load which is pretty consistent with immunostimulatory molecules in this patient population."


-----


It's looking to me as if they're liking the 'once a week' Bavi regimen, since it was used in the very impressive Indian cancer 1B trial, and will be used in the phase 2 cancer trials, and the same 'once a week' is also the bavi schedule for the HCV/HIV trial.

I'm looking forward to seeing what 8 weeks of Bavi monotherapy once a week can do in the HCV/HIV patients, some of which are naive to immunotherapy.

I agree with Brandon that if we see greater than one log it's goooood news, as we'll clearly have a contender for replacing interferon, with equal or better efficacy, with huge advantages in the safety/tolerability profile.



j